James S Goodwin1, Jie Zhou2, Yong-Fang Kuo3, Jacques Baillargeon4. 1. Department of Medicine, University of Texas Medical Branch, Galveston, Texas. Electronic address: jsgoodwi@utmb.edu. 2. Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas. 3. Department of Medicine, University of Texas Medical Branch, Galveston, Texas; Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas; Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas. 4. Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas; Institute for Translational Sciences, University of Texas Medical Branch, Galveston, Texas.
Abstract
OBJECTIVE: To compare the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer vs patients without cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study of a 5% national sample of Medicare patients administered IV bisphosphonate from January 1, 2008, through December 31, 2013, for cancer vs noncancer indications. Probable jaw osteonecrosis was estimated with an algorithm including diagnoses, surgical procedures, and imaging studies. A non-IV bisphosphonate comparison group included patients prescribed an oral bisphosphonate for 30 days or less. RESULTS: During follow-up, 40 (0.42%) out of 9482 patients with cancer developed probable jaw osteonecrosis compared with 8 (0.05%) out of 16,046 patients without cancer. In a Cox multivariable survival analysis controlling for patient characteristics and number of IV zoledronic infusions, patients without cancer had a hazard ratio of 0.17 (95% CI, 0.06-0.46) for developing jaw osteonecrosis compared with those with cancer. The lower rate of jaw osteonecrosis in patients without cancer was also confirmed in a number of sensitivity analyses. CONCLUSION: The low rate of jaw osteonecrosis in patients with osteoporosis who receive IV bisphosphonate should be weighed against the benefit of those agents in preventing hip and other fractures.
OBJECTIVE: To compare the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer vs patients without cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study of a 5% national sample of Medicare patients administered IV bisphosphonate from January 1, 2008, through December 31, 2013, for cancer vs noncancer indications. Probable jaw osteonecrosis was estimated with an algorithm including diagnoses, surgical procedures, and imaging studies. A non-IV bisphosphonate comparison group included patients prescribed an oral bisphosphonate for 30 days or less. RESULTS: During follow-up, 40 (0.42%) out of 9482 patients with cancer developed probable jaw osteonecrosis compared with 8 (0.05%) out of 16,046 patients without cancer. In a Cox multivariable survival analysis controlling for patient characteristics and number of IV zoledronic infusions, patients without cancer had a hazard ratio of 0.17 (95% CI, 0.06-0.46) for developing jaw osteonecrosis compared with those with cancer. The lower rate of jaw osteonecrosis in patients without cancer was also confirmed in a number of sensitivity analyses. CONCLUSION: The low rate of jaw osteonecrosis in patients with osteoporosis who receive IV bisphosphonate should be weighed against the benefit of those agents in preventing hip and other fractures.
Authors: Jacques Baillargeon; Yong Fang Kuo; Yu-Li Lin; Gregg S Wilkinson; James S Goodwin Journal: Ann Pharmacother Date: 2011-09-27 Impact factor: 3.154
Authors: Henrik Gammelager; Rune Erichsen; Sussie Antonsen; Sven Erik Nørholt; Bjarne Neumann-Jensen; Vera Ehrenstein; John Acquavella; Henrik Toft Sørensen Journal: Cancer Epidemiol Date: 2012-04-24 Impact factor: 2.984
Authors: Marc C Hochberg; Desmond E Thompson; Dennis M Black; Sara A Quandt; Jane Cauley; Piet Geusens; Philip D Ross; Dan Baran Journal: J Bone Miner Res Date: 2005-01-18 Impact factor: 6.741
Authors: Patricia Tennis; Kenneth J Rothman; Rhonda L Bohn; Hiangkiat Tan; Athanasios Zavras; Constantinos Laskarides; Brian Calingaert; Mary S Anthony Journal: Pharmacoepidemiol Drug Saf Date: 2012-06-19 Impact factor: 2.890
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Johan Bergdahl; Fredrik Jarnbring; Vera Ehrenstein; Henrik Gammelager; Fredrik Granath; Helle Kieler; Madeleine Svensson; Grethe S Tell; Ylva Trolle Lagerros Journal: Clin Epidemiol Date: 2013-01-04 Impact factor: 4.790
Authors: Sonette Steczina; Candice G T Tahimic; Megan Pendleton; Ons M'Saad; Moniece Lowe; Joshua S Alwood; Bernard P Halloran; Ruth K Globus; Ann-Sofie Schreurs Journal: Sci Rep Date: 2020-04-16 Impact factor: 4.379